Changes for page AstraZeneca

Last modified by Wilton Risenhoover on 2022/07/06 01:12
From version < 7.1 >
edited by Asif Farooqui
on 2022/01/12 13:27
To version < 6.1 >
edited by Asif Farooqui
on 2022/01/12 13:12
< >
Change comment: Uploaded new attachment "AZN4.png", version {1}

Summary

Details

Page properties
Content
... ... @@ -40,7 +40,7 @@
40 40  * 1new molecular entity approval
41 41  
42 42  
43 -[[image:AZN4.png||alt="AZN2.png"]]
43 +[[image:AZN2.png]]
44 44  
45 45  
46 46  === Cambridge ===
... ... @@ -67,34 +67,36 @@
67 67  Looking to the future, Gothenburg has initiated the creation of a new, global cluster for health and life sciences, as part of the GoCo Health Innovation City project, which includes the Gothenburg BioVentureHub. There are currently more than 30 external companies and one academic group co-locating with AstraZeneca at the heart of the Gothenburg site. By facilitating interactions between drug, device, diagnostics and digital health companies, AstraZeneca is creating a dynamic, creative and fertile environment for helping unlock the power of what science can do.
68 68  
69 69  
70 -[[image:AZN2.png]]
71 71  
72 -
73 73  = Therapy Area =
74 74  
75 75  == Oncology ==
76 76  
77 -AstraZeneca has a bold ambition to provide cures for cancer in every form. AstraZeneca is following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.{{footnote}}https://www.astrazeneca.com/our-therapy-areas/oncology.html{{/footnote}}
75 +AstraZeneca has a bold ambition to provide cures for cancer in every form. AstraZeneca is following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
78 78  
77 +[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/oncology.html>>url:https://www.astrazeneca.com/our-therapy-areas/oncology.html]]
79 79  
80 80  The company's Oncology strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. The company's broad pipeline of next-generation medicines, together with its focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers.
81 81  
82 82  The company focus on four strategic priorities:
83 83  
84 -* Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies
85 -* Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients
86 -* Building expertise and leadership in the most prevalent and highest mortality rate tumour types
87 -* Delivering across its global footprint
83 +•Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies
88 88  
85 +•Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients
89 89  
90 -**key disease areas**
87 +•Building expertise and leadership in the most prevalent and highest mortality rate tumour types
91 91  
89 +•Delivering across its global footprint
90 +
91 +key disease areas
92 +
92 92  The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients.
93 93  
95 +BioPharmaceuticals
94 94  
95 -== BioPharmaceuticals ==
97 +Through its work in BioPharmaceuticals, the company want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. There remains a huge unmet need in treating people with chronic diseases. The company's ambition is to stop the progress of these often degenerative, debilitating, and life-threatening  conditions, achieve remission, and one day cure them.
96 96  
97 -Through its work in BioPharmaceuticals, the company want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. There remains a huge unmet need in treating people with chronic diseases. The company's ambition is to stop the progress of these often degenerative, debilitating, and life-threatening  conditions, achieve remission, and one day cure them.{{footnote}}https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html{{/footnote}}
99 +[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html>>url:https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html]]
98 98  
99 99  
100 100  BioPharmaceuticals is responsible for its key therapy areas of Cardiovascular, Renal & Metabolism and Respiratory & Immunology.
... ... @@ -105,16 +105,16 @@
105 105  
106 106  The company will achieve its ambition of transforming healthcare through its talented teams and partners using scientific, medical and commercial innovation.
107 107  
110 +BioPharmaceuticals Business Unit
108 108  
109 -**BioPharmaceuticals Business Unit**
110 -
111 111  The company's commercial teams are transforming how the company bring products to market; engage with patients, healthcare providers and health systems; and deliver healthcare solutions that support them.
112 112  
113 113  
114 -== Cardiovascular, Renal and Metabolism ==
115 +Cardiovascular, Renal and Metabolism
115 115  
116 -The company aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas{{footnote}}https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html{{/footnote}}
117 +The company aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas
117 117  
119 +[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html>>url:https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html]]
118 118  
119 119  Cardiovascular, Renal & Metabolism (CVRM) diseases are the leading causes of death across the globe, killing more than 20 million people each year.
120 120  
AZN5.jpg
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.AsifF
Size
... ... @@ -1,1 +1,0 @@
1 -283.1 KB
Content
This site is funded and maintained by Fintel.io